Every Canadian, regardless of their opinion of the Prime Minister or political affiliation, should feel deeply offended by President Trump's remarks. We might one day be grateful for this WAKE-UP CALL. For too long, we have been complacent in our relationships with the United

Congratulations to Dr. Deborah Siegal for being this year’s national winner of a “young investigator award” from the Canadian Society for Clinical Investigation (CSCI). 🏆 “I am fortunate to be a part of Ottawa's world-class medical research hub which has helped me expand the scope

Proud to be Canadian.

America, give this a listen. This is how our closest allies now view us. MarshFamilySongs

We 👀 you #MikeMyers and you did us proud #CanadaIsNotForSale #ElbowsUp #Never51 #SNL

Dear Doctors of America: Feeling under siege by politics that undermine science and public health? You’re not alone. Some U.S. physicians are already looking north. Ontario needs 3,500 more doctors, and you’d be welcome here. 🧵👇

French MEP Raphaël Glucksmann responds to the White House press secretary’s attack after he suggested France should reclaim the Statue of Liberty: “Dear Americans, since the White House press secretary is attacking me today, I wanted to tell you this:” 1/n

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

A page dedicated to the «#API-CAT study in the #ACC25 daily. Extended treatment in patients with #cancer and #thrombosis Published in NEJM

"The time is now to invest in keeping Canadian #biotech Canadian" 🇨🇦 In a The Globe and Mail op-ed, #PHRI Senior Scientists PJ Devereaux & David Conen, & OBIO's Maura Campbell share how #Canada can better protect & grow its own biotech innovation. theglobeandmail.com/business/comme…

DOM attains a record *82%* success rate in this year’s FRQS competition; plus 2 (out of 6 province-wide) Chercheur(e) de Mérite awards. Congratulations to all! mcgill.ca/x/ixs

Many of us have an influential or inspiring faculty member in mind whom we would like to see recognized. Nominations for the 2025 DOM Awards are now open until June 10th. Details: mcgill.ca/x/iNr

La FMSQ accuse la CAQ de tenter de faire diversion: «le ministre de la Santé a perdu le contrôle» tvanouvelles.ca/2025/05/20/la-…

Fantastic scientific meeting on 6th June 2026 in Brest by our research group Inserm1304_GETBO, with brillant interventions, international leaders in VTE from INNOVTE, in Brest. 70 participants. Les Ateliers des Capucins, F-CRIN, CHU Brest, UBO - Univ. Brest , Inserm, CIC1412 inserm.

So, I signed up to do a thing! Will be trying to set a lifetime PR at the Montreal 10km event this September in support of the MUHC Foundation and the Dept. of Medicine's "Rising Star" program Donations welcome Centre universitaire de santé McGill Fondation CUSM / MUHC Foundation McGill_DOM raceroster.com/events/2025/94…

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Hot off the press! COBBRA trial showed that apixaban is associated with >50% reduced risk of clinically-relevant bleeding symptoms for acute VTE treatment. This can be practice changing! Lana Castellucci Marc Rodger CanVECTOR Network

📸 Ottawa Thrombosis teams enjoying a well-deserved night out and celebrating our successes at #ISTH2025! Proud of the science, the collaboration, and this incredible group. 🩸🥂

🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm SPECTacular findings indeed! 🫁💥

🧠 Diagnosing recurrent VTE is challenging. PREDICTORS study (n=723) showed that existing clinical decision rules (CDRs) identify patients at higher risk and RO recurrence without imaging in ~15% 📊 In low/moderate-risk PE with negative D-dimer: 🟢 0/82 recurrent VTE (0%; 95% CI